PET Radiotracer Market Size and Forecast 2026–2035
The global PET radiotracer market is estimated at USD 4.10 billion in 2025 and is projected to reach USD 8.55 billion by 2035, expanding at a CAGR of 7.62% during 2026–2035.
The commercial structure of PET imaging is becoming substantially more diverse. Fluorodeoxyglucose, or 18F-FDG, remains the most widely established metabolic PET agent, but market growth is increasingly being generated by disease-specific radiotracers targeting prostate-specific membrane antigen, beta-amyloid, tau, somatostatin receptors and myocardial perfusion.
This transition matters commercially because these newer agents do more than identify abnormal metabolism. They increasingly influence treatment selection, disease staging, patient eligibility for targeted therapies and longitudinal care.
The existing DataM Intelligence PET radiotracer study identifies North America as the largest market, Asia-Pacific as the fastest-growing region and a 7.62% market CAGR.
PET Radiotracer Market Definition
PET radiotracers are radioactive diagnostic agents administered to patients before positron emission tomography imaging. They contain a positron-emitting radionuclide linked either to a biologically active molecule or to a molecular targeting compound.
The market covered in this report includes commercially supplied PET diagnostic radiopharmaceuticals such as 18F-FDG, piflufolastat F-18, flotufolastat F-18, fluciclovine F-18, amyloid PET tracers, tau PET tracers, Ga-68 PSMA agents, Ga-68 somatostatin-receptor agents, F-18 myocardial perfusion tracers and other PET agents.
The market excludes PET and PET/CT imaging equipment, SPECT-only agents, therapeutic radionuclides and radiopharmaceutical therapies unless revenue is directly attributable to the diagnostic PET component.
This distinction is increasingly important as radiopharmaceutical companies build integrated theranostic portfolios, pairing diagnostic imaging agents with targeted radionuclide treatments.
Major Hightlites form the Market
2025 Market Size: USD 4.10 Billion
2035 Forecast Market Size: USD 8.55 Billion
CAGR, 2026–2035: 7.62%
Largest Region: North America – 45.2% share
Fastest-Growing Region: Asia-Pacific – 9.6% modeled CAGR
Leading Tracer: 18F-FDG – 38.4% share
Leading Application: Oncology – 62.4% share
Leading End User: Hospitals – 52.8% share
White-Space Opportunity: PET Is Moving from Tumor Detection to Therapy Selection
The most valuable growth opportunity through 2035 is emerging from PET radiotracers that determine what happens after the scan.
Traditional FDG PET is largely used to visualize altered glucose metabolism. Newer radiotracers can identify molecular characteristics that directly affect clinical decisions.
PSMA PET provides one of the clearest examples. The FDA approved PYLARIFY for PET imaging of PSMA-positive lesions in men with prostate cancer, creating a more precise approach to detecting recurrent or metastatic disease.
The commercial significance is already substantial. Lantheus reported USD 989.1 million in PYLARIFY sales during 2025, making one disease-specific PET agent nearly a billion-dollar annual product.
Alzheimer's disease is moving in the same direction.
FDA labeling for amyloid PET agents has evolved as anti-amyloid treatments have entered practice. In 2025, labels for agents including Neuraceq and Amyvid were updated to include use in selecting patients for amyloid-beta-directed therapy.
This converts PET from a diagnostic endpoint into a gatekeeper for expensive disease-modifying therapy.
Cardiology is becoming a third opportunity. FDA approval of Flyrcado (flurpiridaz F 18) in September 2024 introduced an F-18 PET myocardial perfusion imaging agent for adults with known or suspected coronary artery disease.
The common theme is clear: the next generation of PET radiotracer revenue will increasingly come from molecular information that changes treatment selection, not simply from higher scan volumes.
PET Radiotracer Market Key Takeaways
The PET radiotracer market is estimated at USD 4.10 billion in 2025, with oncology accounting for 62.4%, or USD 2.56 billion, of market revenue.
F-18-based agents collectively represent an estimated 75.2% of the market, reflecting the established scale of FDG together with rapidly expanding PSMA, amyloid, tau and cardiac applications.
North America is estimated to hold 45.2% of global revenue, equivalent to USD 1.85 billion, supported by advanced PET infrastructure, higher use of branded molecular imaging agents and favorable commercialization pathways.
Asia-Pacific holds an estimated 22.4% share but is modeled to expand at 9.6% CAGR, faster than the global market.
A major reimbursement change is improving the economics of U.S. PET radiopharmaceutical adoption. Beginning in 2025, CMS finalized separate payment for diagnostic radiopharmaceuticals with a per-day cost above USD 630, rather than packaging the entire cost into the nuclear medicine procedure payment.
Commercial consolidation is also accelerating. In August 2026, Curium and Lantheus announced a definitive merger agreement with a potential transaction value of USD 8.0 billion, subject to shareholder and regulatory approvals and expected to close in the first half of 2027.
PET Radiotracer Industry Trends and Strategic Insights
PSMA PET has created a new commercial benchmark
Prostate-cancer imaging has become one of the largest sources of growth in molecular imaging.
Conventional imaging can miss small or early metastatic lesions. PSMA-directed PET agents bind to a protein expressed at high levels in many prostate cancers, enabling more targeted disease visualization.
PYLARIFY became a commercial leader following FDA approval, while POSLUMA and Ga-68 PSMA agents broadened competition.
In May 2026, Ionetix announced FDA approval of an abbreviated new drug application for gallium Ga-68 gozetotide, with plans to supply PSMA PET doses through its multi-site production network. The product has a three-hour expiration from the end of synthesis, highlighting the logistics intensity of Ga-68 distribution.
Lantheus is also preparing a second-generation formulation. FDA records list PYLARIFY TRUVU, containing piflufolastat F-18, as an approved product in 2026.
The commercial implication is that prostate imaging is no longer a one-product opportunity. Manufacturers increasingly compete on dose availability, geographic reach, production yield and integration with downstream radioligand therapy.
Alzheimer’s treatment is increasing the value of amyloid PET
Neurology is becoming a more commercially important PET market because Alzheimer's care is moving toward biomarker-confirmed treatment.
More than 57 million people worldwide live with dementia, with nearly 10 million new diagnoses each year. Alzheimer's disease accounts for an estimated 60–70% of dementia cases.
Amyloid PET agents include florbetaben F-18, florbetapir F-18 and flutemetamol F-18.
Their role is expanding from diagnostic clarification toward patient selection and therapy management as anti-amyloid medicines require evidence of underlying amyloid pathology.
The strategic importance of the category is reflected in corporate activity. In 2025, Lantheus agreed to acquire Life Molecular Imaging for USD 350 million upfront, with additional milestone payments, gaining the commercial Neuraceq amyloid PET franchise and related neuroimaging assets.
The next competitive area is tau imaging.
As of August 11, 2026, Lantheus' MK-6240 tau PET agent remains under FDA review, with a PDUFA date of August 13, 2026. The agent has been used in nearly 100 active clinical trials, according to the company.
If approved, tau PET would add another commercially relevant biomarker layer to Alzheimer's diagnosis and disease staging.
F-18 is expanding PET myocardial perfusion imaging
Cardiology has historically represented a smaller PET radiotracer segment than oncology, but recent product launches could change its growth profile.
The FDA approved Flyrcado (flurpiridaz F 18) on September 27, 2024, for PET myocardial perfusion imaging in adults with known or suspected coronary artery disease.
GE HealthCare began the U.S. commercial launch in 2025. The product received CMS pass-through payment status effective April 1, 2025, enabling separate payment for the radiopharmaceutical in qualifying hospital outpatient use.
Its F-18 isotope gives the product a distribution advantage over very short-lived cardiac PET agents because doses can be centrally manufactured and transported to imaging centers without requiring an onsite cyclotron.
This could broaden cardiac PET beyond institutions that already maintain specialized isotope-production infrastructure.
Reimbursement is becoming a market-growth lever
PET radiotracers can be significantly more expensive than conventional generic diagnostic agents.
Historically, the U.S. hospital outpatient payment system packaged diagnostic radiopharmaceutical costs into the nuclear-medicine procedure, creating concern that higher-cost tracers could be financially unattractive for providers.
CMS changed that structure for 2025.
Diagnostic radiopharmaceuticals with a per-day cost above USD 630 became separately payable at mean unit cost, while lower-cost products remained packaged. CMS explicitly stated that the change was intended to improve patient access to higher-cost radiopharmaceuticals.
This is particularly relevant to branded PSMA, amyloid and other precision PET agents.
Production and logistics are becoming competitive advantages
PET radiotracers are unusual pharmaceuticals because the product begins losing radioactivity immediately after manufacture.
F-18 has a physical half-life of 110 minutes. Ga-68 is shorter-lived still.
Consequently, market access depends not only on regulatory approval but also on the ability to produce, quality-test, dispense and deliver a patient-specific dose within a narrow time window.
Cardinal Health operates more than 30 PET cyclotron manufacturing facilities in the United States as part of its nuclear pharmacy infrastructure.
Siemens Healthineers' PETNET business expanded its geographic radiopharmaceutical footprint by acquiring Advanced Accelerator Applications' molecular imaging operations from Novartis in late 2024.
Distribution density is therefore becoming a competitive moat alongside the tracer molecule itself.
PET Radiotracer Market Scope
| Metrics | Details |
| Historical Years | 2023–2024 |
| Base Year | 2025 |
| 2025 Market Size | USD 4.10 Billion |
| Forecast Period | 2026–2035 |
| 2035 Market Size | USD 8.55 Billion |
| CAGR | 7.62% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| By Tracer Type | 18F-FDG, Targeted F-18 Radiotracers, Ga-68 Radiotracers, Other PET Radiotracers |
| By Application | Oncology, Neurology, Cardiology, Infectious & Inflammatory Diseases, Others |
| By End User | Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, Others |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, India, Australia, South Korea, Rest of Asia-Pacific |
| Latin America | Brazil, Argentina, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, South Africa, Israel, Türkiye, Rest of MEA |
| Revenue Units | USD Billion |
| Report Insights | Market Size, Forecast, Tracer Share, Application Share, Country Analysis, Pipeline, Reimbursement, Supply Chain, Competitive Positioning |
PET Radiotracer Market Disruption Analysis
PET is shifting from general metabolic imaging toward disease-specific molecular imaging
FDG created the commercial foundation of PET imaging because altered glucose metabolism is useful across many cancers and selected neurological, cardiac and inflammatory conditions.
The next wave is structurally different.
PSMA agents visualize a prostate-cancer-associated target.
Amyloid tracers identify amyloid pathology.
Tau tracers visualize neurofibrillary pathology.
Somatostatin-receptor tracers identify receptor-positive neuroendocrine tumors.
Flyrcado evaluates myocardial perfusion rather than glucose metabolism.
Each new indication therefore increases the number of clinically distinct PET markets rather than simply taking revenue from FDG.
Diagnostic PET and radioligand therapy are converging
The expansion of theranostics is also changing competitive strategy.
A molecular imaging agent can determine whether a tumor expresses the target required for a corresponding radiopharmaceutical therapy. This creates a paired diagnostic-treatment pathway.
PSMA is one of the most advanced examples, where PET imaging identifies PSMA-positive prostate-cancer lesions and can support treatment planning within a broader radioligand-therapy ecosystem.
Somatostatin-receptor imaging plays a similar role for selected neuroendocrine tumors.
Companies that own both imaging and treatment assets can therefore participate in several stages of the patient journey.
The proposed Curium-Lantheus combination illustrates the strategic importance of this model. The companies said the transaction would combine Curium's theranostic and global manufacturing capabilities with Lantheus' U.S. radiodiagnostic portfolio.
Manufacturing quality can determine market access
Radiopharmaceutical approval does not eliminate manufacturing risk.
In June 2026, Lantheus received a Complete Response Letter from the FDA for LNTH-2501, its Ga-68 edotreotide PET imaging kit. The regulatory setback demonstrates how third-party manufacturing and facility readiness can affect commercialization even when the underlying product is clinically advanced.
This makes GMP manufacturing, backup production, validated release testing and supplier redundancy important elements of competitive positioning.
PET Radiotracer Market Dynamics
Rising global cancer incidence supports oncology PET demand
Cancer remains the largest application for PET radiotracers.
IARC's updated GLOBOCAN estimates reported 20.6 million new cancer cases worldwide in 2024, with the annual burden projected to increase substantially over the coming decades.
PET is used across numerous malignancies for staging, restaging, treatment-response assessment and recurrence detection.
The addressable market is also becoming broader as target-specific agents improve imaging in tumors where FDG has limitations.
Prostate cancer is driving precision PET utilization
PSMA imaging has created one of the highest-value diagnostic radiopharmaceutical markets.
The U.S. is projected to record more than 330,000 new prostate-cancer cases in 2026, providing a large underlying patient population for staging and recurrent-disease evaluation.
Not every patient receives PET imaging, but increasing guideline adoption, physician familiarity and tracer availability support continued scan growth.
The near-billion-dollar 2025 revenue generated by PYLARIFY demonstrates that targeted oncology PET can support product economics well beyond the traditional generic-radiotracer model.
Alzheimer’s disease creates a new recurring imaging opportunity
The emergence of disease-modifying Alzheimer's therapy changes the economics of neuro-PET.
PET can be used to confirm pathology before treatment. As treatment pathways become more biomarker driven, repeat or longitudinal imaging may become relevant in selected clinical and research settings.
WHO's latest dementia estimates underscore the size of the underlying disease population, with more than 57 million people affected worldwide.
Improved U.S. reimbursement lowers a key adoption barrier
CMS's decision to separately reimburse diagnostic radiopharmaceuticals above the relevant cost threshold is one of the most important recent structural changes affecting the U.S. market.
The policy reduces the incentive for hospitals to choose a lower-cost tracer solely because a more expensive agent is insufficiently reflected in the bundled procedure payment.
This is likely to matter most for premium branded radiotracers with clear clinical differentiation.
Short half-life remains a structural market restraint
PET radiopharmaceutical logistics cannot be managed like conventional pharmaceuticals.
Production must be timed to patient appointments. Quality-control testing must occur rapidly. Delivery delays can reduce usable radioactivity, while cancelled scans can generate product wastage.
Manufacturers therefore need production capacity close enough to imaging sites to deliver an effective dose within the relevant decay window.
Ionetix's newly approved Ga-68 gozetotide, for example, carries a three-hour expiration from the end of synthesis.
The logistics burden can make smaller cities and lower-volume markets less economical to serve.
Infrastructure requirements limit adoption in emerging markets
PET radiotracers require more than an imaging scanner.
The ecosystem may include cyclotrons, generators, hot cells, radiochemistry systems, cleanrooms, nuclear pharmacists, quality-control laboratories, radiation-safety programs and time-critical logistics.
This high infrastructure requirement partly explains why market revenue remains concentrated in North America, Western Europe, Japan and selected metropolitan Asian markets.
PET Radiotracer Driver Impact Analysis
| Growth Driver | Relative Influence | Primary Market Effect |
| Rising oncology PET utilization | 27% | Sustains FDG and targeted cancer imaging |
| PSMA and other precision PET tracers | 23% | Increases revenue per scan |
| Alzheimer's biomarker-driven treatment | 16% | Accelerates neuro-PET demand |
| Expansion of cardiac PET | 12% | Diversifies market beyond oncology |
| Improved reimbursement | 12% | Supports premium tracer adoption |
| Expansion of radiopharmacy networks | 10% | Improves geographic accessibility |
PET Radiotracer Restraint Impact Analysis
| Market Restraint | Relative Growth Drag | Commercial Impact |
| Short radioisotope half-life and logistics | 28% | Limits geographic distribution |
| Manufacturing and GMP complexity | 23% | Raises capital and regulatory burden |
| PET scanner and infrastructure cost | 18% | Restricts adoption in emerging markets |
| Reimbursement variability | 14% | Affects provider economics |
| Regulatory approval complexity | 10% | Extends commercialization timelines |
| Radiotracer wastage and scheduling risk | 7% | Raises cost per completed scan |
PET Radiotracer Market Segment Analysis
18F-FDG remains the largest individual tracer class with 38.4% share
18F-FDG is estimated to account for 38.4% of global PET radiotracer revenue in 2025, equivalent to around USD 1.57 billion.
Its broad utility across oncology and selected neurological, cardiac and inflammatory indications keeps FDG at the center of PET imaging.
However, its revenue share is forecast to decline gradually even as absolute demand rises.
The reason is not falling relevance. It is the much faster growth of higher-priced disease-specific agents.
Targeted F-18 radiotracers account for 36.8%
Targeted F-18 tracers are estimated to account for 36.8% of 2025 revenue, USD 1.51 billion.
This category includes PSMA tracers such as piflufolastat F-18 and flotufolastat F-18, amyloid agents including florbetaben, florbetapir and flutemetamol, tau imaging products, fluciclovine and F-18 cardiac tracers.
F-18 offers an attractive combination of imaging characteristics and a roughly 110-minute half-life, supporting regional distribution from centralized radiopharmacies.
The rapid growth of branded F-18 products means this segment could overtake FDG in revenue terms during the forecast period.
Ga-68 radiotracers represent 17.9%
Ga-68 agents are estimated to hold 17.9% of global market revenue in 2025, USD 734 million.
Important applications include PSMA imaging and somatostatin-receptor imaging.
Ga-68 can be produced using generator or cyclotron-based approaches depending on the product and manufacturing model, giving providers different infrastructure options.
Its shorter distribution window remains a commercial constraint compared with F-18.
PET Radiotracer Market Share by Tracer Type, 2025
Collectively, F-18-based PET radiotracers account for an estimated 75.2% of 2025 market revenue.
Oncology Holds 62.4% of PET Radiotracer Revenue
Oncology is estimated to account for 62.4% of the global PET radiotracer market in 2025, equivalent to USD 2.56 billion.
Cancer dominates because PET is incorporated across multiple stages of care and because an expanding range of tracers now targets tumor-specific biological characteristics.
FDG remains important in lymphoma, lung cancer, head-and-neck cancer and numerous other malignancies, while PSMA imaging has expanded prostate-cancer PET and somatostatin-receptor agents support neuroendocrine-tumor imaging.
Neurology represents 14.8%
Neurological applications account for an estimated 14.8%, or USD 607 million.
The segment includes cerebral glucose imaging, amyloid imaging and tau imaging.
Alzheimer's disease should be the primary incremental growth driver as biomarker confirmation becomes more closely linked with disease-modifying treatment.
Cardiology holds 11.6%
Cardiology accounts for an estimated 11.6% of 2025 revenue, USD 476 million.
The segment includes myocardial perfusion and viability imaging.
The commercial introduction of Flyrcado adds a distributable F-18 product to a field that historically relied substantially on short-lived PET agents and may therefore increase the number of centers able to offer PET myocardial perfusion imaging.
Hospitals Lead the End-User Segment
Hospitals are estimated to account for 52.8% of global PET radiotracer spending in 2025, or USD 2.16 billion.
Their leadership reflects hospital-based oncology, neurology and cardiology programs as well as access to integrated PET/CT and PET/MRI systems.
Independent and specialist diagnostic imaging centers account for an estimated 35.7%, with academic, clinical-trial and other research settings representing the remaining 11.5%.
| End User | 2025 Market Share | Approx. Revenue |
| Hospitals | 52.80% | USD 2.16 Billion |
| Diagnostic Imaging Centers | 35.70% | USD 1.46 Billion |
| Academic, Research & Others | 11.50% | USD 0.47 Billion |
PET Radiotracer Market Regional Analysis
North America leads with 45.2% global market share
North America is estimated to account for 45.2% of global PET radiotracer revenue in 2025, equal to USD 1.85 billion.
The region's leadership is supported by advanced PET imaging infrastructure, high oncology expenditure, rapid uptake of branded radiopharmaceuticals and a dense production network.
Europe represented the second-largest regional market in 2025, with a 25.8% share and revenue of USD 1.06 billion. The market is projected to expand at an indicative CAGR of 7.2% during 2026–2035, reaching USD 2.12 billion by 2035. Growing modernization initiatives and increasing demand for advanced solutions are expected to contribute to this expansion.
Asia-Pacific accounted for 22.4% of the global market in 2025, generating USD 0.92 billion in revenue. The region is expected to register the fastest growth among the major markets, with an indicative CAGR of 9.6% from 2026 to 2035. Revenue is projected to reach USD 2.30 billion by 2035, driven by rapid industrialization, infrastructure investments, technological advancement, and increasing adoption across emerging economies.
Latin America captured a 4.1% market share in 2025, with revenue estimated at USD 0.17 billion. The regional market is expected to grow at an indicative CAGR of 8.0% during 2026–2035, reaching USD 0.36 billion by 2035. Rising investments in infrastructure and increasing adoption of modern technologies are likely to support market development across the region.
Middle East & Africa accounted for 2.5% of the market in 2025, generating around USD 0.10 billion in revenue. The region is projected to grow at an indicative CAGR of 8.4% between 2026 and 2035, reaching USD 0.23 billion by 2035. Increasing infrastructure development, diversification initiatives, and investments in emerging technologies are expected to create new growth opportunities in the region.
United States PET Radiotracer Market
The United States is estimated to hold 39.0% of global PET radiotracer revenue in 2025, representing around USD 1.60 billion.
The U.S. is the most developed branded PET radiopharmaceutical market.
PYLARIFY alone generated USD 989 million in 2025, illustrating how substantially PSMA imaging has changed the economics of the category.
The reimbursement environment has also become more supportive. CMS began separately paying qualifying high-cost diagnostic radiopharmaceuticals from 2025 when their per-day cost exceeded USD 630.
The U.S. supply chain includes national and regional PET radiopharmacy networks, cyclotron manufacturing sites and specialized nuclear-medicine distributors.
Cardinal Health reports more than 30 PET manufacturing centers with cyclotrons across the United States.
Together, product innovation, reimbursement and infrastructure make the U.S. the primary launch market for many new PET radiotracers.
Canada PET Radiotracer Market
Canada is estimated to represent 4.1% of global revenue in 2025, USD 168 million.
Growth is supported by established academic nuclear-medicine centers and increasing use of molecular imaging in oncology and neurological disease.
The key commercial constraint is geography: Canada's population distribution makes centralized supply of short-half-life products more complicated outside major metropolitan regions.
Europe PET Radiotracer Market
Europe accounts for an estimated 25.8% of global revenue in 2025, USD 1.06 billion.
Germany is the largest modeled European market, followed by the UK and France.
Europe combines mature PET infrastructure with a substantial research ecosystem for novel radiopharmaceuticals.
Manufacturing-network consolidation is also changing the regional landscape. Siemens Healthineers' PETNET business expanded its footprint through the acquisition of Advanced Accelerator Applications' molecular imaging operations, extending its PET radiopharmaceutical network beyond its traditional U.S. base.
The region should also benefit from increasing use of PET biomarkers in prostate cancer, neuroendocrine tumors and Alzheimer's disease.
Germany PET Radiotracer Market
Germany is estimated to account for 5.1% of global market revenue, equivalent to around USD 209 million in 2025.
The country benefits from a dense hospital network, university nuclear-medicine centers and strong adoption of molecular imaging.
Theranostic medicine is particularly relevant because diagnostic PET agents increasingly sit within pathways that connect tumor imaging with targeted radionuclide therapy.
United Kingdom PET Radiotracer Market
The UK represents an estimated 4.7% of global revenue, USD 193 million.
National specialist centers and academic research provide an established foundation for oncology and neurological PET.
Growth through 2035 should increasingly come from targeted oncology and neurodegenerative-disease imaging rather than conventional FDG alone.
France PET Radiotracer Market
France holds an estimated 4.0% share, equivalent to USD 164 million in 2025.
Its established nuclear-medicine infrastructure and radiopharmaceutical expertise make it an important European manufacturing and clinical-research market.
Asia-Pacific PET Radiotracer Market
Asia-Pacific is estimated to account for 22.4% of global PET radiotracer revenue in 2025, equivalent to about USD 918 million.
The region is projected to be the fastest-growing major market, with an indicative CAGR of 9.6% through 2035.
The current DataM Intelligence PET radiotracer study also identifies Asia-Pacific as the fastest-growing region.
Growth will be concentrated in markets expanding PET/CT installation, cyclotron capacity, cancer centers and precision-oncology programs.
China PET Radiotracer Market
China is estimated to account for 6.6% of the global PET radiotracer market in 2025, or around USD 271 million.
Its principal opportunity comes from scale.
Expanding oncology infrastructure and growing use of molecular imaging in major metropolitan hospitals should increase both FDG volumes and adoption of disease-specific tracers.
Local radiopharmaceutical manufacturing is particularly important because PET isotope decay makes long-distance import impractical for many products.
Japan PET Radiotracer Market
Japan is estimated to hold 4.2% of global market revenue, or USD 172 million in 2025.
Japan combines mature imaging infrastructure with an aging population that increases the relevance of oncology, dementia and cardiovascular imaging.
Neurological PET should become increasingly significant as Alzheimer's biomarkers and disease-modifying treatment evolve.
India PET Radiotracer Market
India is estimated to represent 3.1% of global revenue, about USD 127 million in 2025.
Growth is being driven by PET/CT expansion across private hospital networks, cancer centers and metropolitan diagnostic providers.
The main commercial challenge is uneven access. PET services and cyclotron infrastructure remain more concentrated in large urban centers than conventional imaging.
India therefore represents both a scan-volume opportunity and a distribution challenge.
Australia and South Korea PET Radiotracer Market
Australia is estimated to account for 2.2% of global revenue, with South Korea contributing around 2.0%.
Both markets have advanced tertiary healthcare systems and substantial participation in oncology and neurological imaging.
Their relatively mature PET infrastructure makes them attractive launch markets for specialized tracers despite smaller populations.
Latin America PET Radiotracer Market
Latin America is estimated to account for 4.1% of global market revenue in 2025, around USD 168 million.
Brazil is the largest regional market, representing 2.2% of global revenue.
Expansion is closely linked to the availability of cyclotrons and nuclear-medicine centers. Because PET doses cannot be stockpiled for extended periods, growth tends to cluster geographically around production hubs.
The development of more distributed radiopharmacy networks could improve access during the forecast period.
Middle East and Africa PET Radiotracer Market
Middle East and Africa accounts for an estimated 2.5% of global market revenue in 2025, USD 103 million.
Saudi Arabia and the UAE are expected to lead growth in the Gulf through investment in tertiary hospitals, cancer centers and precision medicine.
South Africa remains an important Sub-Saharan nuclear-medicine market.
Across the wider region, the largest constraint is not necessarily demand but the capital and operational infrastructure required to manufacture and deliver PET radiopharmaceuticals reliably.
PET Radiotracer Market Competitive Landscape
The PET radiotracer market is becoming a combination of pharmaceutical innovation and logistics infrastructure.
A company can possess an effective molecular imaging agent and still struggle commercially if it cannot provide reliable doses within the isotope's usable time window.
Lantheus
Lantheus has established one of the strongest PET radiodiagnostic franchises through PYLARIFY and its expanding neurological-imaging portfolio.
PYLARIFY generated USD 989 million in 2025 revenue. The company's pipeline and portfolio also include Neuraceq, PYLARIFY TruVu and the investigational MK-6240 tau tracer.
Its competitive position could change materially following the August 2026 definitive agreement under which Curium plans to acquire Lantheus in a transaction valued at up to USD 8 billion.
Curium
Curium operates across diagnostic and therapeutic nuclear medicine and has a broad international production and distribution footprint.
The proposed Lantheus transaction would significantly expand its presence in U.S. PET radiodiagnostics while strengthening the connection between imaging and theranostic treatment.
The transaction remains subject to closing conditions and is expected to close in the first half of 2027.
GE HealthCare
GE HealthCare competes across PET radiopharmaceuticals, imaging equipment and molecular-imaging technology.
Flyrcado creates a particularly important position in cardiac PET.
The company commercially launched the F-18 myocardial-perfusion product in the United States during 2025 and received CMS pass-through reimbursement status effective April 1, 2025.
Siemens Healthineers/PETNET
PETNET has one of the most extensive dedicated PET radiopharmacy networks.
Its acquisition of Advanced Accelerator Applications' molecular-imaging operations expanded the network internationally and strengthens Siemens Healthineers' ability to support both routine commercial tracers and clinical-development products.
Cardinal Health
Cardinal Health competes primarily through manufacturing, nuclear pharmacy and distribution infrastructure.
Its network includes more than 30 PET cyclotron manufacturing centers in the U.S., making it a critical commercial partner for pharmaceutical companies that require scalable radiopharmaceutical production and time-sensitive delivery.
Other Key Market Participants
Other relevant participants include Blue Earth Diagnostics/Bracco, Eli Lilly, Jubilant Radiopharma, ABX Advanced Biochemical Compounds, IBA, Ionetix and regional radiopharmacy manufacturers.
The current DataM Intelligence market page also identifies Blue Earth Diagnostics, ABX, Cardinal Health, IBA, Eli Lilly, GE HealthCare, Jubilant Pharma, Lantheus and Siemens Healthineers among companies active in the market.
PET Radiotracer Company Positioning Matrix
| Position | Representative Companies | Competitive Strength |
PET Radiodiagnostic Leaders | Lantheus, GE HealthCare | Branded high-value PET products |
Global Nuclear Medicine Platforms | Curium, Siemens Healthineers/PETNET | Manufacturing and international distribution |
Distribution & Manufacturing Leaders | Cardinal Health, PETNET | Cyclotron and radiopharmacy reach |
Oncology Imaging Specialists | Blue Earth Diagnostics/Bracco, Lantheus | PSMA and precision-oncology imaging |
| Neuroimaging Players | Lantheus/Life Molecular Imaging, Eli Lilly, GE HealthCare | Amyloid and tau PET portfolios |
Emerging Infrastructure Players | Ionetix and regional PET manufacturers | Local isotope production and supply expansion |
Recent PET Radiotracer Market Developments
August 3, 2026: Curium and Lantheus announced a definitive merger agreement under which Curium will acquire Lantheus. Total potential transaction value is USD 8.0 billion, including contingent value rights. The transaction is expected to close in the first half of 2027, subject to approvals and other closing conditions.
June 26, 2026: Lantheus received an FDA Complete Response Letter for LNTH-2501 (Ga-68 edotreotide), illustrating the continuing importance of manufacturing and facility compliance in radiopharmaceutical commercialization.
May 26, 2026: Ionetix announced FDA ANDA approval for gallium Ga-68 gozetotide, expanding commercial supply options for PSMA PET imaging.
March 2026: FDA product records added PYLARIFY TRUVU, a piflufolastat F-18 product, expanding Lantheus' PSMA PET franchise.
June 2025: FDA labeling for major amyloid PET products including Neuraceq and Amyvid was updated to support their evolving role in selecting patients for amyloid-beta-directed therapy.
April 1, 2025: Flyrcado received CMS traditional pass-through status in the U.S., supporting separate reimbursement in qualifying hospital outpatient settings.
March 2025: GE HealthCare commercially launched Flyrcado in the United States following its 2024 FDA approval.
January 2025: Lantheus announced an agreement to acquire Life Molecular Imaging for USD 350 million upfront plus potential milestone payments, strengthening its Alzheimer's PET portfolio.
December 2024: Siemens Healthineers' PETNET completed the acquisition of Advanced Accelerator Applications' molecular-imaging operations from Novartis, expanding its PET radiopharmaceutical manufacturing network.
September 27, 2024: The FDA approved Flyrcado for PET myocardial perfusion imaging in adults with known or suspected coronary artery disease.
PET Radiotracer Procurement Priorities
Hospitals and diagnostic imaging networks do not select PET radiotracers solely on image quality.
Dose reliability is critical. A tracer that arrives after its scheduled administration window may no longer contain sufficient radioactivity for the planned scan.
Distance from production matters because the economic delivery radius varies according to isotope half-life and formulation.
Clinical differentiation is becoming more important as providers choose between multiple tracers within the same disease area.
Reimbursement and coding can materially change the financial attractiveness of a tracer, particularly for premium branded products.
Manufacturing redundancy is increasingly valuable. Buyers and distributors need to understand whether a supplier has backup cyclotrons, alternate radiopharmacies and validated contingency plans.
Image-reading requirements also matter. New molecular targets may require physician training and standardized interpretation.
Integration with therapy is becoming another purchasing criterion where a diagnostic PET result determines eligibility for a corresponding targeted treatment.
Strategic Opportunity Areas Through 2035
Disease-specific F-18 tracers
F-18 combines useful imaging properties with a distribution window that supports centralized manufacturing. This gives new F-18 PSMA, neurological and cardiac products a commercially scalable route into imaging centers without onsite isotope production.
Alzheimer’s disease imaging
Amyloid PET is becoming increasingly linked to treatment selection, while tau imaging could provide a second biomarker-driven growth category.
Cardiac PET
Flyrcado provides the market with an F-18 myocardial-perfusion product that can be distributed beyond facilities capable of producing ultra-short-lived cardiac isotopes.
Theranostic imaging
PSMA and somatostatin-receptor PET illustrate how a diagnostic radiotracer can serve as the entry point to radionuclide therapy.
Regional manufacturing
Asia-Pacific, Latin America and the Middle East offer significant unmet access potential, but commercial growth depends on local or regional manufacturing because radioisotope decay prevents conventional global pharmaceutical distribution.
Why Choose DataM Intelligence?
- DataM Intelligence evaluates the PET radiotracer market as a pharmaceutical and supply-chain ecosystem rather than treating PET imaging as a single equipment-driven market.
- The report quantifies market size across tracer type, therapeutic area, end user, region and major countries.
- Its oncology analysis differentiates traditional FDG use from high-growth PSMA, neuroendocrine and other target-specific imaging.
- The neurology section assesses the impact of amyloid and tau biomarkers on the evolving Alzheimer's treatment pathway.
- Cardiac analysis tracks the effect of new F-18 myocardial-perfusion agents and reimbursement developments.
- The study also examines cyclotron capacity, radiopharmacy networks, isotope half-life, manufacturing risk, regulatory approvals and reimbursement-factors that determine whether a tracer can translate clinical efficacy into commercial scale.
Target Audience
- PET radiopharmaceutical manufacturers
- pharmaceutical and biotechnology companies
- nuclear pharmacies
- cyclotron operators
- hospitals
- PET imaging centers
- radiology groups
- nuclear-medicine departments
- oncology companies
- Alzheimer's drug developers
- cardiovascular imaging companies
- diagnostic companies
- contract manufacturers
- healthcare investors
- distributors
- academic research centers
- radiopharmaceutical logistics providers
